Market volatility derails Novartis' plan to sell stake in its India arm
Novartis AG's plan to sell its 70.68% stake in Novartis India faces challenges due to market volatility impacting valuation.
PMLive9h
Novartis’ Pluvicto granted FDA approval for expanded prostate cancer use
Novartis’ radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has been approved by the US Food and Drug ...
Medical Marketing & Media1d
Novartis names new chief legal and compliance officer as Klaus Moosmayer exits
Karen Hale, who joined Novartis in 2021 as chief legal officer, will take on the new chief legal and compliance officer role.
Fierce Pharma4d
Novartis' prostate cancer drug Pluvicto wins key FDA nod toward $5B-plus sales target
After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...
BioPharma Dive3d
FDA broadens use of Novartis’ radiopharma drug Pluvicto
Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...
Swiss drugmakers Novartis and Roche ditch some diversity programmes on US concerns
Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...
Novartis scraps use of diverse panels for hires in US
By Paul Arnold and Maggie Fick ZURICH (Reuters) -Swiss drugmaker Novartis is ending its use of diverse panels for all of its ...
Medical Dialogues1d
Novartis appoints Karen Hale as Chief Legal and Compliance Officer
Basel: Novartis has announced the appointment of Karen Hale to the expanded role of Chief Legal and Compliance Officer for ...
Yahoo Finance12d
Novartis builds case for new SMA gene therapy
To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. On Wednesday, Novartis gave a more ...
Pharmabiz1d
Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC
Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC: Basel Monday, March 31, 2025, 13:00 Hrs [IST] Novartis anno ...
Fierce Pharma13d
Novartis details intrathecal Zolgensma data in bid to reach more SMA patients with gene therapy
A pair of clinical data sets gives Novartis confidence in a new formulation of the company’s gene therapy Zolgensma for the ...
Novartis11d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Basel, March 20, 2025 – Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G) ...